Pulse Biosciences (NASDAQ: PLSE) is a bioelectronic medicine company that develops and commercializes pulsed electric field technology for medical and biological applications. The company is listed on the Nasdaq Capital Market and filed its most recent annual report on February 19, 2026, covering the fiscal year ended in 2025. The filing excerpts provided do not contain sufficient detail to describe specific revenue streams, segment breakdowns, customer concentrations, competitive positioning, geographic mix, or leadership with the specificity required for a grounded description. Based solely on the available filing excerpts, Pulse Biosciences is a development-stage or early-commercial bioelectronic company pursuing FDA regulatory clearance and approval processes for its technology, with forward-looking disclosures centered on clinical studies, regulatory filings, and procedure adoption rather than established recurring revenue.

Source: SEC 10-K, filed 2026-02-19

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories DarioHealth Corp Electromed Inc LENSAR Inc Lucid Diagnostics Inc Neuronetics Inc Neuropace Inc PAVmed Inc